[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586374":3},{"organization":4,"outcomesModule":7,"designInfo":34,"detailedDescription":40,"studyPopulation":33,"armGroups":41,"interventions":48,"overallOfficials":53,"centralContacts":57,"locations":67,"responsibleParty":144,"collaborators":146,"id":149,"slug":33,"hasResults":150,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":150,"sex":155,"minAge":156,"maxAge":33,"enrollmentInfo":157,"targetDuration":33,"studyType":160,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":70,"whyStopped":33,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},{"fullName":5,"class":6},"University Hospital Schleswig-Holstein","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":33},[9],{"measure":10,"description":11,"timeFrame":12},"GU and GI Toxicity","Late toxicity measured with Radiation Therapy Oncology Group-(RTOG)-Score","12-15 months after radiotherapy",[14,18,22,26,30],{"measure":15,"description":16,"timeFrame":17},"Acute toxicity","Acute toxicity analysed by Adverse Event (AE)- and Serious Adverse Event (SAE)-reports","Through study completion",{"measure":19,"description":20,"timeFrame":21},"PSA","Prostate Specific Antigen (PSA)","At the time of inclusion and 1, 3, 6-9 and 12-15 months after radiotherapy",{"measure":23,"description":24,"timeFrame":25},"IPSS","International Prostate Symptom Score (IPSS) on a scale 0-35 with lower being better","Screening and 3, 6-9 and 12-15 months after radiotherapy",{"measure":27,"description":28,"timeFrame":29},"Quality of Life Score","EORTC Quality of Life Questionnaire (QLQ) C30 on a scale 0-100 with higher being better","At the time of inclusion and 12-15 months after radiotherapy",{"measure":31,"description":32,"timeFrame":29},"Decision Regret Score","Decision Regret Score on a scale 0-100 with lower being lower regret",null,{"allocation":35,"interventionModel":36,"interventionModelDescription":33,"primaryPurpose":37,"observationalModel":33,"timePerspective":33,"maskingInfo":38},"NA","SINGLE_GROUP","TREATMENT",{"masking":39,"maskingDescription":33,"whoMasked":33},"NONE","Experimental radiosurgery of the prostate with 3 fractions each with 9.5 -10.5 Gy (total application rate of 28.5-31.5 Gy) based on risk grading.\n\nPlanned visits are: Baseline, visits at every radiation day and four follow ups (4-6 weeks, 3 months, 6 months and one year after last day of radiation).",[42],{"label":43,"type":44,"description":45,"interventionNames":46},"Hypofractionated Radiosurgery","EXPERIMENTAL","3 fractions with 9.5-10.5 Gy, total dose 28.5-31.5 Gy",[47],"Radiation: Hypofractionated Radiosurgery",[49],{"type":50,"name":43,"description":51,"armGroupLabels":52,"otherNames":33},"RADIATION","Image-guided stereotactic Linac based RT preferable with \"dedicated radiosurgery system\" such as CyberKnife",[43],[54],{"name":55,"affiliation":5,"role":56},"David Krug, MD","PRINCIPAL_INVESTIGATOR",[58,63],{"name":59,"role":60,"phone":61,"phoneExt":33,"email":62},"Oliver Blanck, PhD","CONTACT","+4943150026666","oliver.blanck@uksh.de",{"name":64,"role":60,"phone":65,"phoneExt":33,"email":66},"Frauke Walther-Clausnizer","+4943150026581","Frauke.Walther-Clausnizer@uksh.de",[68,88,94,104,115,128],{"facility":69,"status":70,"city":71,"state":72,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"Saphir Radiosurgery Center Frankfurt am Main","RECRUITING","Frankfurt am Main","Hesse","60528","Germany","DE",{"type":77,"coordinates":78},"Point",[79,80],8.68417,50.11552,{"lat":80,"lon":79},[83,87],{"name":84,"role":60,"phone":85,"phoneExt":33,"email":86},"Christian Arnold, MD","+496967735910","arnold@saphir-rc.com",{"name":84,"role":56,"phone":33,"phoneExt":33,"email":33},{"facility":89,"status":90,"city":71,"state":72,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":91,"geoPoint":93,"contacts":33},"University Hospital Frankfurt","SUSPENDED",{"type":77,"coordinates":92},[79,80],{"lat":80,"lon":79},{"facility":95,"status":70,"city":96,"state":72,"zip":97,"country":74,"countryCode":75,"cosmosGeoPoint":33,"geoPoint":33,"contacts":98},"European Radiosurgery Center Munich","Munich","81377",[99,103],{"name":100,"role":60,"phone":101,"phoneExt":33,"email":102},"Alexander Muacevic, MD","+49894523360","alexander.muacevic@erc-munich.com",{"name":100,"role":56,"phone":33,"phoneExt":33,"email":33},{"facility":105,"status":106,"city":107,"state":108,"zip":109,"country":74,"countryCode":75,"cosmosGeoPoint":110,"geoPoint":114,"contacts":33},"Saphir Radiosurgery Center Norther Germany","ACTIVE_NOT_RECRUITING","Kiel","Schleswig-Holstein","24105",{"type":77,"coordinates":111},[112,113],10.13489,54.32133,{"lat":113,"lon":112},{"facility":116,"status":70,"city":107,"state":108,"zip":109,"country":74,"countryCode":75,"cosmosGeoPoint":117,"geoPoint":119,"contacts":120},"University Medical Center Schleswig-Holstein",{"type":77,"coordinates":118},[112,113],{"lat":113,"lon":112},[121,125,126],{"name":122,"role":60,"phone":123,"phoneExt":33,"email":124},"Stefan Huttenlocher, MD","+494312398990","stefan.huttenlocher@uksh.de",{"name":55,"role":56,"phone":33,"phoneExt":33,"email":33},{"name":122,"role":127,"phone":33,"phoneExt":33,"email":33},"SUB_INVESTIGATOR",{"facility":129,"status":70,"city":130,"state":131,"zip":132,"country":74,"countryCode":75,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"CyberKnife Centrum Mitteldeutschland","Erfurt","Thuringia","99089",{"type":77,"coordinates":134},[135,136],11.03536,50.97734,{"lat":136,"lon":135},[139,143],{"name":140,"role":60,"phone":141,"phoneExt":33,"email":142},"Hans-Ulrich Herold, MD","+4936178172310","Hans-Ulrich.Herold@ckcm.de",{"name":140,"role":56,"phone":33,"phoneExt":33,"email":33},{"type":145,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR",[147],{"name":148,"class":6},"University of Luebeck","100586374",false,"NCT06914544","Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III)","HYPOSTAT-III","Inclusion Criteria:\n\n* Localised, histopathologically confirmed Prostate Cancer (cT1-T2c N0 M0)\n* Gleason-grade ≤7, ISUP Grade Group 1-3\n* Guideline-based staging\n* Age ≥ 18 years\n* PSA \\\u003C 20 ng\u002Fml\n* Volume of the prostate \\\u003C 80 cm³\n* IPSS-Score ≤ 12\n* Written informed consent\n\nExclusion Criteria:\n\n* History of prior pelvic radiotherapy\n* Previous transurethral resection, laser enucleation or prostate ablation\n* Contraindication to MRI or Fiducial marker implantation (e.g. gold allergy)\n* Relevant comorbidity thought to adversely affect treatment compliance\n* Legal incapacity or lack of informed consent","MALE","18 Years",{"count":158,"type":159},175,"ESTIMATED","INTERVENTIONAL",[35],"Hypofractionated radiosurgery with 5 fractions is considered standard of care for localized prostate cancer. The investigators initiated this multicenter phase II prospective trial to analyse feasibility (toxicity) of hypofractionated radiosurgery with 3 fractions in patients with localised prostate cancer under the hypothesis that the ratio of patients with late GU and GI toxicity ≥ grade 2 after 1 year amounts to 8.4% and 1.3% and is significant lower than 16.4% and 5.7% currently.",[164],"Prostate Cancer",[164,166,167,168,169],"SBRT","CyberKnife","Radiosurgery","HYPOSTAT","2026-04-28",{"date":172,"type":173},"2026-04-29","ACTUAL",{"date":175,"type":173},"2025-12-10",{"date":177,"type":159},"2029-12-31",{"name":5,"class":6},6]